Search Results - "Cuello, Héctor A."

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients by Segatori, Valeria I., Cuello, Héctor A., Gulino, Cynthia A., Albertó, Marina, Venier, Cecilia, Guthmann, Marcelo D., Demarco, Ignacio A., Alonso, Daniel F., Gabri, Mariano R.

    Published in Cancer Immunology, Immunotherapy (01-08-2018)
    “…Antitumor strategies based on positive modulation of the immune system currently represent therapeutic options with prominent acceptance for cancer patients’…”
    Get full text
    Journal Article
  2. 2

    Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers by Cuello, Hector A, Sinha, Saptarshi, Verhagen, Andrea L, Varki, Nissi, Varki, Ajit, Ghosh, Pradipta

    Published in JCI insight (11-07-2024)
    “…Carcinomas are common in humans but rare among closely related "great apes." Plausible explanations, including human-specific genomic alterations affecting the…”
    Get full text
    Journal Article
  3. 3

    Terminally sialylated and fucosylated complex N-glycans are involved in the malignant behavior of high-grade glioma by Cuello, Hector A, Ferreira, Gretel M, Gulino, Cynthia A, Toledo, Alejandro Gomez, Segatori, Valeria I, Gabri, Mariano R

    Published in Oncotarget (29-12-2020)
    “…Gliomas are the most common intracranial primary tumors, for which very few therapeutic options are available. The most malignant subtype is the glioblastoma,…”
    Get full text
    Journal Article
  4. 4

    Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab by Cuello, Hector A., Segatori, Valeria I., Alberto, Marina, Pesce, Analía, Alonso, Daniel F., Gabri, Mariano R.

    “…Background Biosimilars are described as biological products that resemble the structure of original biologic therapeutic products, with no clinically…”
    Get full text
    Journal Article
  5. 5

    Aberrant O-glycosylation modulates aggressiveness in neuroblastoma by Cuello, Hector A, Segatori, Valeria I, Albertó, Marina, Gulino, Cynthia A, Aschero, Rosario, Camarero, Sandra, Mutti, Laura Galluzzo, Madauss, Kevin, Alonso, Daniel F, Lubieniecki, Fabiana, Gabri, Mariano R

    Published in Oncotarget (25-09-2018)
    “…Neuroblastoma (NB) is the most common pediatric malignancy diagnosed before the first birthday in which MYCN oncogene amplification is associated with poor…”
    Get full text
    Journal Article
  6. 6

    Abstract 6648: Racotumomab and PD-1 blockade combination exhibits an additive antitumor effect in a non-small cell lung cancer model by Segatori, Valeria I., Gulino, Cynthia A., Capobianco, Carla S., Rojo, Selene, Ferreira, Gretel M., Cuello, Héctor A., Gabri, Mariano R., Alonso, Daniel A.

    Published in Cancer research (Chicago, Ill.) (15-08-2020)
    “…N-glycolylneuraminic acid (NeuGc) is a sialic acid molecule present in mammalian cells as terminal constituents of membrane glycoconjugates such as…”
    Get full text
    Journal Article